CBUS
Cibus, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.59
+0.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.3M | 3.6M | 4.3M | 1.8M | 157.0K |
| Cost of Revenue | 2.4M | 5.9M | 6.9M | 395.0K | 1.5M |
| Gross Profit | 2.0M | (2.3M) | (2.6M) | 1.4M | (1.4M) |
| Operating Expenses | |||||
| R&D Expense | 37.4M | 44.2M | 50.4M | 42.4M | 11.6M |
| SG&A Expense | 19.7M | 26.9M | 30.8M | 28.9M | 9.4M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.2M) | (5.9M) | (6.9M) | 249.0M | — |
| Total Operating Expenses | 55.9M | 65.2M | 74.4M | 320.3M | 21.0M |
| Cost and Expenses | 58.3M | 71.1M | 81.2M | 320.7M | 22.5M |
| Operating Income (EBIT) | (53.9M) | (67.5M) | (77.0M) | (318.9M) | (22.4M) |
| Non-Operating | |||||
| Interest Income | 352.0K | 438.0K | 631.0K | 527.0K | 60.0K |
| Interest Expense | 18.8M | 35.5M | 34.2M | 18.9M | 87.0K |
| Net Interest Income | (18.5M) | (35.0M) | (33.6M) | (18.4M) | (27.0K) |
| Other Non-Op Income/Expense | (45.7M) | (64.7M) | (205.7M) | (18.8M) | 5.5M |
| Non-Operating Income (excl Interest) | 8.7M | 29.2M | 171.5M | (132.0K) | (5.6M) |
| EBT (Pre-Tax Income) | (99.6M) | (132.2M) | (282.7M) | (337.6M) | (16.9M) |
| Income Tax Expense | 13.0K | 29.0K | 29.0K | (4.0K) | — |
| Bottom Line | |||||
| Net Income | (98.2M) | (127.1M) | (251.4M) | (267.6M) | (16.9M) |
| Earnings from Cont. Ops | (99.6M) | (132.2M) | (282.7M) | (337.6M) | (16.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (98.2M) | (127.1M) | (251.4M) | (267.6M) | (16.9M) |
| Per Share | |||||
| Basic EPS | ($1.65) | ($2.78) | ($10.83) | ($25.95) | ($18.36) |
| Diluted EPS | ($1.65) | ($2.78) | ($10.83) | ($25.95) | ($18.36) |
| Revenue Per Share | $0.06 | $0.08 | $0.18 | $0.18 | $0.17 |
| Shares | |||||
| Basic Shares Outstanding | 76.8M | 45.8M | 23.2M | 10.3M | 919950 |
| Diluted Shares Outstanding | 76.8M | 45.8M | 23.2M | 10.3M | 919950 |
| Profitability Metrics | |||||
| EBITDA | (58.9M) | (90.8M) | (241.6M) | (314.6M) | (15.2M) |
| D&A | 3.7M | 5.9M | 6.9M | 4.7M | 1.5M |
| EBIT | (62.6M) | (96.7M) | (248.5M) | (318.8M) | (16.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026